In all analyses, people experiencing uncontrolled asthma symptoms saw improvements in their breathing by adding Spiriva Respimat to an ICS or combination ICS/LABA.

Boehringer Ingelheim has announced new analyses that provide further evidence that adding Spiriva Respimat improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.

"Many people with asthma continue to live with uncontrolled symptoms. These new analyses show that adding Spiriva Respimat to another maintenance treatment may improve breathing, even for people whose symptoms may be harder to control, such as those with higher body mass index or people who have both asthma and allergies," said Danny McBryan, Head of Clinical Development & Medical Affairs, COPD & Asthma, Boehringer Ingelheim Pharmaceuticals, Inc. "These analyses are examples of Boehringer Ingelheim's commitment to scientific research that helps improve understanding of who may best benefit from our medicines."